Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 11; p. 1529
• Main Authors: Shchulkin, Aleksey V, Erokhina, Pelageya D, Goncharenko, Anna V, Mylnikov, Pavel Yu, Chernykh, Ivan V, Abalenikhina, Yulia V, Kotliarova, Maria S, Yakusheva, Elena N
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023
• Subjects: ABCB1; Antioxidants; Brain research; Care and treatment; Complications and side effects; Composition; Dabigatran etexilate; Dosage and administration; Drug therapy; Drugs; drug–drug interaction; Enzymes; Ethylmethylhydroxypyridine succinate; Gastrointestinal system; Ischemia; Metabolism; Permeability; Prevention; Proteins; Rifampin; Risk factors; Scientific equipment and supplies industry; SLCO1B1; Stroke (Disease); Succinates; Russia; United States

2-Ethyl-6-methyl-3-hydroxypyridine succinate (EMHPS, Mexidol) is an original antioxidant and an anti-ischemic drug with the possibility of wide applications in the complex therapy of diseases, accompanied by the development of oxidative stress and ischemia; for example, ischemic stroke, chronic cere...